GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G1 Therapeutics Inc (NAS:GTHX) » Definitions » 3-Year Book Growth Rate

G1 Therapeutics (G1 Therapeutics) 3-Year Book Growth Rate : -47.30% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is G1 Therapeutics 3-Year Book Growth Rate?

G1 Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $0.53.

During the past 12 months, G1 Therapeutics's average Book Value per Share Growth Rate was -39.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was -47.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was -41.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of G1 Therapeutics was 12.30% per year. The lowest was -47.30% per year. And the median was -35.70% per year.

Competitive Comparison of G1 Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, G1 Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

G1 Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G1 Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where G1 Therapeutics's 3-Year Book Growth Rate falls into.


G1 Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

G1 Therapeutics  (NAS:GTHX) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

G1 Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of G1 Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

G1 Therapeutics (G1 Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G1 Therapeutics Inc (NAS:GTHX) » Definitions » 3-Year Book Growth Rate
Comparable Companies
HRGN OMGA DMAC ARMP ATOS APLM IPSC GLYC SGMT ACHV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
G1H:Germany
Address
700 Park Offices Drive, Suite 200, Research Triangle Park, NC, USA, 27709
Website
https://www.g1therapeutics.com
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies.
Executives
John V. Umstead officer: Chief Financial Officer C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Rajesh Malik officer: Chief Medical Officer 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Mark Avagliano officer: Chief Business Officer 79 T.W. ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Terry L Murdock officer: Chief Operating Officer
Bailey John E. (jack) Jr. director, officer: President and CEO C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Andrew Perry officer: Chief Commercial Officer C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Mark A. Velleca director, officer: President and CEO 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Monica R. Thomas officer: General Counsel 700 PARK OFFICES, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Jennifer K. Moses officer: CFO 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
James S. Hanson officer: General Counsel 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Norman Sharpless director 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 22709
Jacks Lee director 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Seth Rudnick director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS, MISSISSAUGA A6 L5N 0E4
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421
Soma Gupta officer: Chief Commercial Officer C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709